# Jaime Mejia

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jaime-mejia/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,907 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 16 |
| i10-index | 23 |
| Last Known Institution | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| OpenAlex ID | https://openalex.org/A5080084854 |
| ORCID iD | 0000-0002-1315-6878 |
| Works | 104 |

## Researcher papers

- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple/)
- [Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](https://scholariq.org/papers/pharmacogenomic-predictor-of-sensitivity-to-preoperative-chemotherapy-with/)
- [Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-investigator-choice-chemotherapy-for-metastatic-triple/)
- [Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial](https://scholariq.org/papers/pembrolizumab-plus-trastuzumab-in-trastuzumab-resistant-advanced-her2-positive/)
- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple-2/)
- [Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study](https://scholariq.org/papers/determination-of-oestrogen-receptor-status-and-erbb2-status-of-breast-carcinoma/)
- [Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer](https://scholariq.org/papers/microtubule-associated-protein-tau-is-a-bifunctional-predictor-of-endocrine/)
- [Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer](https://scholariq.org/papers/phase-3-study-comparing-the-use-of-docetaxel-on-an-every-3-week-versus-weekly/)
- [Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)](https://scholariq.org/papers/abstract-pd5-03-relationship-between-tumor-infiltrating-lymphocytes-tils-and/)
- [Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.](https://scholariq.org/papers/association-of-tumor-mutational-burden-tmb-and-clinical-outcomes-with/)
- [Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study](https://scholariq.org/papers/real-world-perioperative-treatment-patterns-and-economic-burden-of-recurrence-in/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research/)

## Researcher university

- [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.